• Профілактична сальпінгектомія – необхідність чи варіант норми?

Профілактична сальпінгектомія – необхідність чи варіант норми?

HEALTH OF WOMAN.2016.7(113):34–39 
 

Профілактична сальпінгектомія – необхідність чи варіант норми? 
 

Веропотвелян П. М., Цехмістренко І. С., Веропотвелян М. П., Воленко Н. В.

ОКЗ «Міжобласний центр медичної генетики і пренатальної діагностики», м. Кривий Ріг

Перинатальний центр, м. Київ


У статті показана необхідність проведення симультанної сальпінгектомії пацієнткам під час гістеректомії. За даними аналізу публікацій описано наукове обґрунтування операції при різному ступені ризику розвитку серозного раку яєчників. Дискутується роль методу у підвищенні ефективності лікування безплідності. Аналіз літературних даних свідчить, що після сальпінгектомії може сформуватися вторинна недостатність яєчників. Це закономірно пояснюється негативними наслідками дефіциту естрогенів, які можуть перевищувати користь від зниження захворюваності на рак яєчників та профілактики запальних захворювань органів малого таза.


Ключові слова: гістеректомія, сальпінгектомія, рак яєчників, оваріальний резерв.


Литература:

1. Matorras R. Hysteroscopic hydrosalpinx occlusion with Essure device in IVF patients when salpingectomy or laparoscopy is contraindicated /A. Rabanal, B. Prieto B., Diez S., Brouard I., Mendoza R. et al. Eur. J. Obstet. Gynecol. Reprod. Biol. – 2013. – V. 169(1). – P. 54–9. http://dx.doi.org/10.1016/j.ejogrb.2013.02.008; PMid:23561020

2. Findley A.D. Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial /M.T. Siedhoff, K.A. Hobbs, J.F. Steege, E.T. Carey, C.A. McCall et al. //Fertil. Steril. – 2013. – V. 100(6). – P. 1704–8. http://dx.doi.org/10.1016/j.fertnstert.2013.07.1997

3. Hill M.J. Ovarian reserve and subsequent assisted reproduction outcomes after methotrexate therapy for ectopic pregnancy or pregnancy of unknown location /J.C. Cooper, G. Levy, C. Alford, K.S. Richter, A.H. DeCherney et al. //Fertil. Steril. – 2014. – V. 101(2). – P. 413–9. http://dx.doi.org/10.1016/j.fertnstert.2013.10.027; PMid:24269042 PMCid:PMC3946660

4. Uyar I. Effect of single-dose methotrexate on ovarian reserve in women with ectopic pregnancy /O.U. Yucel, C. Gezer, I. Gulhan, B. Karis, H.M. Hanhan et al. //Fertil. Steril. – 2013. – V. 100 (5). – P. 1310-3. http://dx.doi.org/10.1016/j.fertnstert.2013.06.040; PMid:23891021

5. Wiser A. Effects of treatment of ectopic pregnancy with methotrexate or salpingectomy in the subsequent IVF cycle /A. Gilbert, R. Nahum, R. Orvieto, J. Haas, A. Hourvitz et al. //Reprod. Biomed. Online. – 2013. – V. 26(5). – P. 449–53. http://dx.doi.org/10.1016/j.rbmo.2013.01.018; PMid:23518030

6. Xi W. Ovarian response to gonadotropins after laparoscopic salpingectomy for ectopic pregnancy /F.Gong, Y. Tang, H. Zhang, G. Lu //Int. J. Gynaecol. Obstet. – 2012. – V. 116(2). – P. 93–6. http://dx.doi.org/10.1016/j.ijgo.2011.10.009; PMid:22103980

7. Yi Q.H. Evaluation of the clinical value of simultaneous hysterectomy and bilateral salpingectomy in perimenopausal women /S.R. Ling, K.M. Chen, W.R. He, L. Li, C.J. Yi // Zhonghua Fu Chan Ke Za Zhi. – 2012. – V. 47 (2). – P. 110–4. PMid:22455742

8. Meng X.H. Effect of salpingectomy on ovarian function /Y.M. Zhu // Zhejiang Da Xue Xue Bao Yi Xue Ban. – 2006. – V. 35(5). – P. 555–9. PMid:17063552

9. Ni L. Influence of various tubal surgeries to serum antimullerian hormone level and outcome of the subsequent IVF-ET treatment /S. Sadiq, Y. Mao, Y. Cui, W. Wang, J. Liu //Gynecol. Endocrinol. – 2013. – V. 29(4). – P. 345–9. http://dx.doi.org/10.3109/09513590.2012.743004; PMid:23339657

10. Sezik M. Total salpingectomy during abdominal hysterectomy: effects on ovarian reserve and ovarian stromal blood flow /O. Ozkaya, F. Demir, H.T. Sezik, H.J. Kaya //J. Obstet. Gynaecol. Res. – 2007. – V.33(6). – P. 863–9. http://dx.doi.org/10.1111/j.1447-0756.2007.00669.x

11. Petrov I.A. Prophylactic salpingectomy /O.A. Tihonovskaya, A.O. Okorokov, I.I. Kupriyanova, A.S. Fateeva, M.S. Petrova, S.V. Logvinov // Obstetrics and gynecology. – 2016. – V. 2. – P. 36–42. http://dx.doi.org/10.18565/aig.2016.2.36-42

12. Ulug P. Evaluation of the effects of single or multiple dose methotrexate administration, salpingectomy on ovarian reserve of rat with the measurement of anti-Mьllerian hormone (AMH) levels. http://dx.doi.org/10.1016/j.ejogrb.2014.07.011; PMid:25171264

and histological analysis /G. Oner //Eur. J. Obstet. Gynecol. Reprod. Biol. – 2014. – V. 181. – P. 205–9.

13. Dobrokhotova J. E., ed. Clinical lectures on obstetrics and gynecology / J.E. Dobrokhotova, A.E. Boyar, L.A. Haidar et al. //Moscow: GEOTAR-Media. – 2009. – P. 312.

14. Strizhakov A.N. Ovarian reserve in patients with endometrioid ovarian cysts after laparoscopic surgery using a surgical high energies /A.I. Davydov, R.D. Musayev. In the book: G.T. Sukhikh, L.V. Adamyan . New technologies in the diagnosis and treatment of gynecological diseases. – M., 2011. – P. 101–2.

15. Iwase A. Assessment of ovarian reserve using anti-Mьllerian hormone levels in benign gynecologic conditions and surgical interventions: a systematic narrative review /T. Nakamura, T. Nakahara, M. Goto, F. Kikkawa //Reprod. Biol. Endocrinol. – 2014. – V. 12. – P. 125. http://dx.doi.org/10.1186/1477-7827-12-125; PMid:25510324 PMCid:PMC4274680

16. Mukhopadhaya N. The hysterectomy story in the United Kingdom /I.T. Manyonda //Midlife Health. – 2013. – V. 4 (1). – P. 40–1. http://dx.doi.org/10.4103/0976-7800.109635

17. Schenberg T. Prophylactic bilateral salpingectomy as a prevention strategy in women at high-risk of ovarian cancer: a mini-review /G. Mitchell //Front. Oncol. – 2014. – V. 4. – P. 21. http://dx.doi.org/10.3389/fonc.2014.00021; PMid:24575389 PMCid:PMC3918654

18. Vorwergk J. Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate /M.P. Radosa, K. Nicolaus, N. Baus, J. Jimenez Cruz, M. Rengsberger et al. //J. Cancer Res. Clin. Oncol. – 2014. – V. 140 (5). – P. 859–65. http://dx.doi.org/10.1007/s00432-014-1622-6; PMid:24573653

19. Chan C.C. Ovarian changes after abdominal hysterectomy for benign conditions /E.H. Ng, P.C. Ho //J. Soc. Gynecol. Investig. – 2005. – V. 12 (1). – P. 54–7. http://dx.doi.org/10.1016/j.jsgi.2004.07.004; PMid:15629673

20. Nahбs E.A. Inhibin B and ovarian function after total abdominal hysterectomy in women of reproductive age /A. Pontes, P. Traiman, J. Nahбs-Neto, I. Dalben, L. De Luca //Gynecol. Endocrinol. – 2003. – V.17(2). – P. 125–31. http://dx.doi.org/10.1080/713603218http://dx.doi.org/10.1080/gye.17.2.125.131; PMid:12737673

21. Vuorento T. Follow-up of ovarian endocrine function in premenopausal women after hysterectomy by daily measurements of salivary progesterone /J. Mдenpдд, I. Huhtaniemi //Clin. Endocrinol. (Oxf). – 1992. – V.36(5). – P. 505–10. http://dx.doi.org/10.1111/j.1365-2265.1992.tb02253.x

22. Chalmers C. Hysterectomy and ovarian function: levels of follicle stimulating hormone and incidence of menopausal symptoms are not affected by hysterectomy in women under age 45 years /M. Lindsay, D. Usher, P. Warner, D. Evans, M. Ferguson //Climacteric. – 2002. – V.5(4). – P. 366–73. http://dx.doi.org/10.1080/cmt.5.4.366.373http://dx.doi.org/10.1080/713605316; PMid:12626216

23. Ciarmela P. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications /M.S. Islam, F.M. Reis, P.C. Gray, E. Bloise, F. Petraglia et al. //Hum. Reprod. Update. – 2011. – V. 17 (6). – P. 772–90. http://dx.doi.org/10.1093/humupd/dmr031

24. Nahбs E.A. Effect of total abdominal hysterectomy on ovarian blood supply in women of reproductive age /A. Pontes, J. Nahas-Neto, V.T. Borges, R. Dias, P. Traiman //J. Ultrasound Med.- 2005. – V. 24 (2). – P. 169–74.

25. Bhattacharya S. A comparison of bladder and ovarian function two years following hysterectomy or endometrial ablation /J. Mollison, S. Pinion, D.E. Parkin, D.R. Abramovich, P. Terry et al. //Br. J. Obstet. Gynaecol. – 1996. – V. 103 (9). – P. 898–903. http://dx.doi.org/10.1111/j.1471-0528.1996.tb09909.x; PMid:8813310

26. Aylamazyan E. Gynecology from puberty to menopause. – M., 2004. – P. –409.

27. Morelli M. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere /R. Venturella, R. Mocciaro, A. Di Cello, E. Rania, D. Lico et al.. //Gynecol. Oncol. – 2013. – V.129(3). – P. 448–51. http://dx.doi.org/10.1016/j.ygyno.2013.03.023

28. Colgan T.J. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status /J. Murphy, D.E. Cole, S. Narod, B. Rosen //Am. J. Surg. Pathol. – 2001. – V. 25 (10). – P. 1283–9. http://dx.doi.org/10.1097/00000478-200110000-00009

29. Piek J.M. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer /P.J. van Diest, R.P. Zweemer, J.W. Jansen, R.J. Poort-Keesom, F.H. Menko et al. //J. Pathol. – 2001. – V. 195 (4). – P. 451–6. http://dx.doi.org/10.1002/path.1000; PMid:11745677

30. Crum C.P. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer /R. Drapkin, D. Kindelberger, F. Medeiros, A. Miron, Y. Lee //Clin. Med. Res. – 2007. – V.5(1). – P. 35–44. http://dx.doi.org/10.3121/cmr.2007.702

31. Salvador S. The fallopian tube: primary site of most pelvic high-grade serous carcinomas / B. Gilks, M. Kцbel, D. Huntsman, B. Rosen, D. Miller //Int. J. Gynecol. Cancer. – 2009. – V.19(1). – P. 58–64. http://dx.doi.org/10.1111/igc.0b013e318199009c

32. Leblanc E. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development /F. Narducci, I. Farre, J.P. Peyrat, S. Taieb, C. Adenis et al. // Gynecol. Oncol.- 2011. – V.121(3). – P. 472–6. http://dx.doi.org/10.1016/j.ygyno.2011.02.012

33. Greene M.H. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? /P.L. Mai, P.E. Schwartz //Am. J. Obstet. Gynecol. – 2011. – V.204(1). – P. 19. e1-6. http://dx.doi.org/10.1016/j.ajog.2010.05.038; PMid:20619389 PMCid:PMC3138129

34. Repasy I. Effect of the removal of the Fallopian tube during hysterectomy on ovarian survival: the orphan ovary syndrome /V. Lendvai, A. Koppan, J. Bodis, M. Koppan // Eur. J. Obstet. Gynecol. Reprod. Biol. – 2009. – V. 144(1). – P. 64–7. http://dx.doi.org/10.1016/j.ejogrb.2008.12.019; PMid:19261370

35. Morse A.N. The risk of hydrosalpinx formation and adnexectomy following tubal ligation and subsequent hysterectomy: a historical cohort study /C.B. Schroeder, J.F. Magrina, M.J. Webb, P.C. Wollan, B.P. Yawn //Am. J. Obstet. Gynecol. – 2006. – V.194(5). – P. 1273–6. http://dx.doi.org/10.1016/j.ajog.2005.11.014; PMid:16579950

36. Ghezzi F. Infectious morbidity after total laparoscopic hysterectomy: does concomitant salpingectomy make a difference? /A. Cromi, G. Siesto, V. Bergamini, F. Zefiro, P. Bolis //BJOG. – 2009. – V.116(4). – P. 589–93. http://dx.doi.org/10.1111/j.1471-0528.2008.02085.x

37. Ouldamer L. Fallopian tube prolapse after hysterectomy: a systematic review /A. Caille, G. Body //PLoS One. – 2013. – V.8(10). – e76543. http://dx.doi.org/10.1371/journal.pone.0076543; PMid:24116117 PMCid:PMC3792027

38. Parihar M. Hydrosalpinx functional surgery or salpingectomy? The importance of hydrosalpinx fluid in assisted reproductive technologies /A. Mirge, R. Hasabe //J. Gynecol. Endosc. Surg. – 2009. – V.1(1). – P. 12–6. http://dx.doi.org/10.4103/0974-1216.51903; PMid:22442504 PMCid:PMC3304258

39. Dechaud H. What effect does hydrosalpinx have on assisted reproduction? The role of salpingectomy remains controversial /B. Hedon //Hum. Reprod. – 2000. – V.15(2). – P. 234–5. http://dx.doi.org/10.1093/humrep/15.2.234; PMid:10655289

40. Strandell A. Hydrosalpinx and IVF outcome: a prospective, randomized multicentre trial in Scandinavia on salpingectomy prior to IVF /A. Lindhard, U. Waldenstrцm, J. Thorburn, P.O. Janson, L. Hamberger //Hum. Reprod. – 1999. – V. 14 (11). – P. 2762–9. http://dx.doi.org/10.1093/humrep/14.11.2762

41. Johnson N.P. Surgical treatment for tubal disease in women due to undergo in vitro fertilization /S. van Voorst, M.C. Sowter, A. Strandell, B.W. Mol //Cochrane Database Syst. Rev. – 2010. – V. (1). – CD002125. PMid:20091531

42. Bontis J.N. Laparoscopic management of hydrosalpinx /T.D. Theodoridis //Ann. N.Y. Acad. Sci. – 2006. – V. 1092. – P. 199–210. http://dx.doi.org/10.1196/annals.1365.017; PMid:17308145

43. Strandell A. Why does hydrosalpinx reduce fertility? The importance of hydrosalpinx fluid /A. Lindhard //Hum. Reprod. – 2002. – V. 17 (5). – P. 1141–5. http://dx.doi.org/10.1093/humrep/17.5.1141; PMid:11980729

44. Atilgan R. Investigation of the effects of unilateral total salpingectomy on ovarian proliferating cell nuclear antigen and follicular reserve: experimental study /T. Kuloрlu, A. Boztosun, U. Orak, M. Baspinar, B. Can et al. //Eur. J. Obstet. Gynecol. Reprod. Biol. – 2015. – V. 188 (1). – P. 56–60. http://dx.doi.org/10.1016/j.ejogrb.2015.02.028; PMid:25790915

45. Gelbaya T.A. Ovarian response to gonadotropins after laparoscopic salpingectomy or the division of fallopian tubes for hydrosalpinges /L.G. Nardo, C.T. Fitzgerald, G. Horne, D.R. Brison, B.A. Lieberman //Fertil. Steril. – 2006. – V. 85 (5). – P. 1464–8. http://dx.doi.org/10.1016/j.fertnstert.2005.10.036; PMid:16580673

46. Grynnerup A.G. Anti-Mьllerian hormone levels in salpingectomized compared with nonsalpingectomized women with tubal factor infertility and women with unexplained infertility /A. Lindhard, S. Sшrensen //Acta Obstet. Gynecol. Scand. – 2013. – V. 92 (11). – P. 1297–303. http://dx.doi.org/10.1111/aogs.12234; PMid:24032634

47. Nakagawa K. Laparoscopic proximal tubal division can preserve ovarian reserve for infertility patients with hydrosalpinges /S. Ohgi, A. Nakashima, T. Horikawa, M. Irahara, H.J. Saito //J. Obstet. Gynaecol. Res. – 2008. – V. 34 (6). – P. 1037–42. http://dx.doi.org/10.1111/j.1447-0756.2008.00801.x

48. Ye X.P. A retrospective analysis of the effect of salpingectomy on serum anti-Mьllerian hormone level and ovarian reserve / Yang Y.Z., Sun X.X. //Am. J. Obstet. Gynecol. – 2015. – V.212(1):53. – P.1-10.

49. Ashrafyan L.A. Systematic errors in the therapeutic approaches for ovarian cancer //Practical oncology. Practical Oncology. – V. 15, № 4. – 2014.

50. Кочеткова Е.О., Дегемерзанова Н.К. Риск развития рака молочной железы и яичников, обусловленный мутациями генов BRCA1, BRCA2, CHEK2. Казахстанский Медицинский Журнал №4 (34) июль-август, 2013 г.